HomeCompareYOKE vs JNJ

YOKE vs JNJ: Dividend Comparison 2026

YOKE yields 0.92% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.3K in total portfolio value· pulled ahead in Year 6
10 years
YOKE
YOKE
● Live price
0.92%
Share price
$27.54
Annual div
$0.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.0K
Annual income
$97.84
Full YOKE calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — YOKE vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYOKEJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YOKE + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YOKE pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YOKE
Annual income on $10K today (after 15% tax)
$78.33/yr
After 10yr DRIP, annual income (after tax)
$83.16/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,902.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YOKE + JNJ for your $10,000?

YOKE: 50%JNJ: 50%
100% JNJ50/50100% YOKE
Portfolio after 10yr
$25.6K
Annual income
$2,393.62/yr
Blended yield
9.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

YOKE
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YOKE buys
0
JNJ buys
0
No recent congressional trades found for YOKE or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYOKEJNJ
Forward yield0.92%2.13%
Annual dividend / share$0.25$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$21.0K$30.3K
Annual income after 10y$97.84$4,689.40
Total dividends collected$952.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YOKE vs JNJ ($10,000, DRIP)

YearYOKE PortfolioYOKE Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,792$92.16$10,592$272.30+$200.00YOKE
2$11,641$92.95$11,289$357.73+$352.00YOKE
3$12,549$93.70$12,123$472.89+$426.00YOKE
4$13,522$94.40$13,141$629.86+$381.00YOKE
5$14,564$95.07$14,408$846.81+$156.00YOKE
6← crossover$15,679$95.69$16,021$1,151.60$342.00JNJ
7$16,872$96.28$18,122$1,588.22$1.3KJNJ
8$18,150$96.83$20,930$2,228.20$2.8KJNJ
9$19,518$97.35$24,792$3,191.91$5.3KJNJ
10$20,982$97.84$30,274$4,689.40$9.3KJNJ

YOKE vs JNJ: Complete Analysis 2026

YOKEStock

YOKE is an actively managed ETF that invests tactically across broad US and non-US equity markets. It aims to hold one-third of its assets in each of the following strategies based on: i) momentum, ii) quality, and ii) risk-on/ risk-off environment. For momentum, the fund identifies the current stage of the business cycle and selects securities that display positive momentum. For quality, the fund employs proprietary qualitative and quantitative fundamental indicators to assess attractiveness and future returns. Lastly, the risk-on/risk-off strategy adjusts investments based on market valuations and risk levels, shifting towards defensive equity positions when necessary. While the fund generally buys securities directly, it may also invest in cost-efficient ETFs. Foreign exposure is typically attained through investments in ADRs and GDRs, as well as ETFs with exposure to developed market equities. Portfolio holdings are generally sold at the discretion of the adviser.

Full YOKE Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this YOKE vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YOKE vs SCHDYOKE vs JEPIYOKE vs OYOKE vs KOYOKE vs MAINYOKE vs ABBVYOKE vs MRKYOKE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.